Literature DB >> 11956813

Genes involved in hepatocellular carcinoma: deregulation in cell cycling and apoptosis.

Andrea Tannapfel1, Christian Wittekind.   

Abstract

Hepatocellular carcinoma (HCC) accounts for 80-90% of liver cancers and is one of the most frequent carcinomas throughout the world. The disease is more prevalent in parts of Africa and Asia than in North and South America and Europe, with a strong etiological association with viral hepatitis, hemochromatosis, known liver (hepatic) carcinogens, and toxins (mycotoxins). Clinical and molecular medical analyses have yielded a considerable amount of information about liver carcinogenesis. Many genes undergo somatic aberrations, with a tendency to cluster at genes involved in cell cycle regulation, in the p53 and Wnt/catenin pathways of signal transduction and cellular adhesion, and in the TGF-beta/IGF axis. Since HCC may arise both in liver cirrhosis and in noncirrhotic liver, one may speculate that different hepatocarcinogenetic pathways exist. Recent results of high-output gene analysis using cDNA microarrays support the idea of different genetic alterations in HCC with or without cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11956813     DOI: 10.1007/s00428-002-0617-x

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  29 in total

Review 1.  [Methylation and other new concepts for the origin of hepatocellular carcinoma].

Authors:  A Tannapfel
Journal:  Pathologe       Date:  2006-07       Impact factor: 1.011

2.  p53 Promotes proteasome-dependent degradation of oncogenic protein HBx by transcription of MDM2.

Authors:  Lingling Xian; Jing Zhao; Jia Wang; Zhou Fang; Bo Peng; Wenzhang Wang; Xiaona Ji; Long Yu
Journal:  Mol Biol Rep       Date:  2009-10-16       Impact factor: 2.316

Review 3.  β-Catenin Signaling and Roles in Liver Homeostasis, Injury, and Tumorigenesis.

Authors:  Satdarshan Pal Monga
Journal:  Gastroenterology       Date:  2015-03-05       Impact factor: 22.682

4.  Thymoquinone suppression of the human hepatocellular carcinoma cell growth involves inhibition of IL-8 expression, elevated levels of TRAIL receptors, oxidative stress and apoptosis.

Authors:  Abdelkader E Ashour; Adel R Abd-Allah; Hesham M Korashy; Sabry M Attia; Abdelrahman Z Alzahrani; Quaiser Saquib; Saleh A Bakheet; Hala E Abdel-Hamied; Shazia Jamal; Arun K Rishi
Journal:  Mol Cell Biochem       Date:  2014-01-08       Impact factor: 3.396

5.  Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: a multi-institutional analysis.

Authors:  Dean J Arnaoutakis; Michael N Mavros; Feng Shen; Sorin Alexandrescu; Amin Firoozmand; Irinel Popescu; Matthew Weiss; Christopher L Wolfgang; Michael A Choti; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2014-01       Impact factor: 5.344

Review 6.  DNA methylation in hepatocellular carcinoma.

Authors:  Iris Tischoff; Andrea Tannapfe
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

7.  Promoter methylation and mRNA expression of DKK-3 and WIF-1 in hepatocellular carcinoma.

Authors:  Zhen Ding; Ye-Ben Qian; Li-Xin Zhu; Qi-Ru Xiong
Journal:  World J Gastroenterol       Date:  2009-06-07       Impact factor: 5.742

Review 8.  [Gallbladder and bile duct carcinoma. Biology and pathology].

Authors:  A Tannapfel; C Wittekind
Journal:  Internist (Berl)       Date:  2004-01       Impact factor: 0.743

9.  Dramatic down-regulation of oxidoreductases in human hepatocellular carcinoma hepG2 cells: proteomics and gene ontology unveiling new frontiers in cancer enzymology.

Authors:  Lambert C M Ngoka
Journal:  Proteome Sci       Date:  2008-10-24       Impact factor: 2.480

10.  Detection of aberrant p16INK4A methylation in sera of patients with liver cirrhosis and hepatocellular carcinoma.

Authors:  Hyung Jun Chu; Jeong Heo; Soo Boon Seo; Gwang Ha Kim; Dae Hwan Kang; Geun Am Song; Mong Cho; Ung Suk Yang
Journal:  J Korean Med Sci       Date:  2004-02       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.